Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Tuberculosis

Free Subscription Articles published in Emerg Infect Dis Retrieve available abstracts of 33 articles: HTML format

Single Articles

September 2022
1. KHERABI Y, Frechet-Jachym M, Rioux C, Yazdanpanah Y, et al
   Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
   Emerg Infect Dis. 2022;28:1796-1804.
   PubMed     Abstract available
   
   
   
2. CAMPBELL JR, Nsengiyumva P, Chiang LY, Jamieson F, et al
   Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016.
   Emerg Infect Dis. 2022;28:1814-1823.
   PubMed     Abstract available
   
   
   
3. LAEMMLE-RUFF I, Graham SM, Williams B, Horyniak D, et al
   Detecting Mycobacterium tuberculosis Infection in Children Migrating to Australia.
   Emerg Infect Dis. 2022;28:1833-1841.
   PubMed     Abstract available
   
   
   July 2022
4. SHEA J, Smith C, Halse TA, Kohlerschmidt D, et al
   Novel Mycobacterium tuberculosis Complex Genotype Related to M. caprae.
   Emerg Infect Dis. 2022;28:1431-1436.
   PubMed     Abstract available
   
   
   May 2022
5. LE RAY LF, Aubry A, Sougakoff W, Revest M, et al
   atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.
   Emerg Infect Dis. 2022;28:1062-1064.
   PubMed     Abstract available
   
   
   April 2022
6. WINGLEE K, Hill AN, Langer AJ, Self JL, et al
   Decrease in Tuberculosis Cases during COVID-19 Pandemic as Reflected by Outpatient Pharmacy Data, United States, 2020.
   Emerg Infect Dis. 2022;28:820-827.
   PubMed     Abstract available
   
   
   March 2022
7. HASAN T, Nguyen VN, Nguyen HB, Nguyen TA, et al
   Retrospective Cohort Study of Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020.
   Emerg Infect Dis. 2022;28:684-692.
   PubMed     Abstract available
   
   
   
8. KHAN A, Phares CR, Phuong HL, Trinh DTK, et al
   Overseas Treatment of Latent Tuberculosis Infection in US-Bound Immigrants.
   Emerg Infect Dis. 2022;28:582-590.
   PubMed     Abstract available
   
   
   
9. NATAPRAWIRA HM, Gafar F, Risan NA, Wulandari DA, et al
   Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia.
   Emerg Infect Dis. 2022;28:660-671.
   PubMed     Abstract available
   
   
   November 2021
10. AUNG HL, Nyunt WW, Fong Y, Biggs PJ, et al
    Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar.
    Emerg Infect Dis. 2021;27:2847-2855.
    PubMed     Abstract available
    
    
    August 2021
11. PAPAVENTSIS D, Dougas G, Kalkouni O, Karabela S, et al
    Occupational Exposure to Zoonotic Tuberculosis Caused by Mycobacterium caprae, Northern Greece, 2019.
    Emerg Infect Dis. 2021;27:1997-1999.
    PubMed     Abstract available
    
    
    
12. LOUIE JK, Agraz-Lara R, Romo L, Crespin F, et al
    Tuberculosis-Associated Hospitalizations and Deaths after COVID-19 Shelter-In-Place, San Francisco, California, USA.
    Emerg Infect Dis. 2021;27:2227-2229.
    PubMed     Abstract available
    
    
    
13. GHIELMETTI G, Kupca AM, Hanczaruk M, Friedel U, et al
    Mycobacterium microti Infections in Free-Ranging Red Deer (Cervus elaphus).
    Emerg Infect Dis. 2021;27:2025-2032.
    PubMed     Abstract available
    
    
    July 2021
14. SOKO RN, Burke RM, Feasey HRA, Sibande W, et al
    Effects of Coronavirus Disease Pandemic on Tuberculosis Notifications, Malawi.
    Emerg Infect Dis. 2021;27:1831-1839.
    PubMed     Abstract available
    
    
    June 2021
15. TALWAR A, Li R, Langer AJ
    Association between Birth Region and Time to Tuberculosis Diagnosis among Non-US-Born Persons in the United States.
    Emerg Infect Dis. 2021;27:1645-1653.
    PubMed     Abstract available
    
    
    April 2021
16. DE VAL BP, Romero B, Tortola MT, Leon LH, et al
    Polyresistant Mycobacterium bovis Infection in Human and Sympatric Sheep, Spain, 2017-2018.
    Emerg Infect Dis. 2021;27:1241-1243.
    PubMed     Abstract available
    
    
    March 2021
17. MALIK AA, Gandhi NR, Lash TL, Cranmer LM, et al
    Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan.
    Emerg Infect Dis. 2021;27:805-812.
    PubMed    
    
    
    
18. LAFLEUR M, Reuter KE, Hall MB, Rasoanaivo HH, et al
    Drug-Resistant Tuberculosis in Pet Ring-Tailed Lemur, Madagascar.
    Emerg Infect Dis. 2021;27:977-979.
    PubMed     Abstract available
    
    
    
19. WALTER KS, Tatara MB, Esther da Silva K, Moreira FMF, et al
    Local and Travel-Associated Transmission of Tuberculosis at Central Western Border of Brazil, 2014-2017.
    Emerg Infect Dis. 2021;27:905-914.
    PubMed     Abstract available
    
    
    
20. NGUYEN HV, Nguyen HB, Nguyen NV, Cobelens F, et al
    Decline of Tuberculosis Burden in Vietnam Measured by Consecutive National Surveys, 2007-2017.
    Emerg Infect Dis. 2021;27:872-879.
    PubMed     Abstract available
    
    
    
21. FAROOQ HZ, Cirillo DM, Hillemann D, Wyllie D, et al
    Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs.
    Emerg Infect Dis. 2021;27:985-987.
    PubMed     Abstract available
    
    
    
22. NONGHANPHITHAK D, Chaiprasert A, Smithtikarn S, Kamolwat P, et al
    Clusters of Drug-Resistant Mycobacterium tuberculosis Detected by Whole-Genome Sequence Analysis of Nationwide Sample, Thailand, 2014-2017.
    Emerg Infect Dis. 2021;27:813-822.
    PubMed     Abstract available
    
    
    
23. CUEVAS LE, Santos VS, Lima SVMA, Kontogianni K, et al
    Systematic Review of Pooling Sputum as an Efficient Method for Xpert MTB/RIF Tuberculosis Testing during the COVID-19 Pandemic.
    Emerg Infect Dis. 2021;27:719-727.
    PubMed     Abstract available
    
    
    
24. ZETOLA NM, Moonan PK, Click E, Oeltmann JE, et al
    Population-Based Geospatial and Molecular Epidemiologic Study of Tuberculosis Transmission Dynamics, Botswana, 2012-2016.
    Emerg Infect Dis. 2021;27:835-844.
    PubMed     Abstract available
    
    
    
25. TAZERART F, Saad J, Niar A, Sahraoui N, et al
    Mycobacterium bovis Pulmonary Tuberculosis, Algeria.
    Emerg Infect Dis. 2021;27:972-974.
    PubMed     Abstract available
    
    
    
26. CHITWOOD MH, Pelissari DM, Marques da Silva GD, Bartholomay P, et al
    Trends in Untreated Tuberculosis in Large Municipalities, Brazil, 2008-2017.
    Emerg Infect Dis. 2021;27:957-960.
    PubMed     Abstract available
    
    
    
27. MILLER MA, Kerr TJ, de Waal CR, Goosen WJ, et al
    Mycobacterium bovis Infection in Free-Ranging African Elephants.
    Emerg Infect Dis. 2021;27:990-992.
    PubMed     Abstract available
    
    
    January 2021
28. LEAVITT SV, Jacobson KR, Ragan EJ, Bor J, et al
    Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa.
    Emerg Infect Dis. 2021;27:728-739.
    PubMed     Abstract available
    
    
    December 2020
29. MANDALAKAS AM, Kay AW, Bacha JM, Devezin T, et al
    Tuberculosis among Children and Adolescents at HIV Treatment Centers in Sub-Saharan Africa.
    Emerg Infect Dis. 2020;26.
    PubMed    
    
    
    November 2020
30. HALEY CA, Macias P, Jasuja S, Jones BA, et al
    Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
    Emerg Infect Dis. 2020;27.
    PubMed     Abstract available
    
    
    
31. HOPEWELL PC, Reichman LB, Castro KG
    Parallels and Mutual Lessons in Tuberculosis and COVID-19 Transmission, Prevention, and Control.
    Emerg Infect Dis. 2020;27.
    PubMed     Abstract available
    
    
    March 2020
32. KERR TJ, Gumbo R, Goosen WJ, Rogers P, et al
    Novel Techniques for Detection of Mycobacterium bovis Infection in a Cheetah.
    Emerg Infect Dis. 2020;26:630-631.
    PubMed     Abstract available
    
    
    
33. POORANSINGH S, Sakhamuri S
    Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations.
    Emerg Infect Dis. 2020;26:624-625.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: